SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Abgenix, Inc. (ABGX)
An SI Board Since December 1998
Posts SubjectMarks Bans
590 38 0
Emcee:  Henry Niman Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
565Amgen to Acquire Abgenix for $22.50 Per Share Wednesday December 14, 4:06 pm ET John McCarthy-12/14/2005
564THANK YOU FOR HAVING ME HOLD ON. tlrk, now abgx, how much amgen will i have amopgcw-12/14/2005
563clinicalcolorectalcancer.comJohn McCarthy-12/13/2005
562CURAGEN Announces Preliminary Top-line Phase II Results on Velafermin Tuesday DeJohn McCarthy-12/13/2005
561Antibody-Based Therapies for Colorectal Cancer theoncologist.alphamedpress.org John McCarthy-12/6/2005
560SG Cowen & Co. analyst Eric Schmidt AP Imclone Systems Shares Down on RepoJohn McCarthy-12/5/2005
559Thumbs Ups Abgenix In early November, Amgen/NASDAQ: AMGN and Abgenix/NASDAQ: AJohn McCarthy-12/5/2005
558Zacks.com Announces That Nadine Wong Highlights: Amgen and Abgenix (Note:I triJohn McCarthy-12/5/2005
557A117 (About (EGFr and CRC)) Comparison of Epidermal Growth Factor Receptor LevJohn McCarthy-11/14/2005
556A269 Epidermal Growth Factor (EGFR), K-Ras and B-Raf Mutation Status and CliniJohn McCarthy-11/14/2005
555A230 Human Cancer Xenograft Studies of Angiogenesis Inhibitor YN968D1 as an AnJohn McCarthy-11/14/2005
554Sorafenib (BAY 43-9006) A236 Phase II Study of First Line Sorafenib (BAY 43-900John McCarthy-11/14/2005
553these abstracts are from the SAME SOURCE and look at ERBITUX .... aacr.org ===John McCarthy-11/14/2005
552AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuJohn McCarthy-11/14/2005
551Denosumab (AMG 162) (ABGX): 2 year study results at ACR meeting] Note: I swipedJohn McCarthy-11/14/2005
550Mode of action of monoclonals: informational (from a Yahoo post) healthvalue.neJohn McCarthy-11/14/2005
549Thank you John. That fills my void. Stable is not stable, which I should have fitom pope-11/12/2005
548tom this is not intended to preclude Dew's answer ... and is more of a at yJohn McCarthy-11/12/2005
547Does "stable disease" mean that the malignancy is no longer progressintom pope-11/12/2005
546>> 33% of patients experienced a partial or complete response. 46% of patiDewDiligence_on_SI-11/12/2005
545Cancer News Article Note:I did not see this trial posted on this board so I thJohn McCarthy-11/12/2005
544I'll probably attend the following event (you can pre-register at www.biosf.JMarcus-11/11/2005
543Almost the polar opposite of Goldman’s view in #517.DewDiligence_on_SI-11/10/2005
542rkrw - thanks for your input ... regards, JohnJohn McCarthy-11/10/2005
541tom - thanks ... for the confirmation ... regards, JohnJohn McCarthy-11/10/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News